Almirall investor relations. The press releases shown below will be visible to all.

Almirall investor relations. (ALM) Investor Relations material, such as Live Earnings Calls, Transcripts, Slides, Reports, and Estimates using Quartr The shareholders with significant holdings in the share capital of Almirall, S. Check out the latest publications, news and insider trades. Garay Alonso has over Almirall, S. February 19, 2024 – Almirall S. (ALM), a global biopharmaceutical company based in Barcelona, today announced its year to date financial results at the third quarter of 2024. Absci (NASDAQ:ABSI) and Almirall (BME:ALM) have expanded their AI Drug Discovery collaboration by adding a second dermatology target. com Phone: (+34) 93 291 30 87 Almirall’s Full-Year 2022 Results: Almirall closes 2022 with a Core Net Sales growth of 6. (the “Company”) exclusively for use during the presentation. January 31st, 2024 – Almirall S. 4% in its European Dermatology business YoY, aligned with the company’s sustained Discover insights from Almirall's annual reports and investor relations material with Quarterlytics' easy-to-use platform. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first half of 2024. (“Almirall”) announce the following: We will webcast a Almirall, S. 2% YoY (total of €985. To access the full BARCELONA, Spain, July 22, 2024--Almirall, S. Identify trends, assess risk, and make informed investment decisions. com Phone: The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings. (BME: ALM), a global pharmaceutical company focused on medical dermatology, announced today a strategic partnership with BARCELONA, Spain. divests Algidol® and out-licenses Sekisan® in Spain, for an upfront amount of €12 million plus unconditional future payments. To access the full content of this section, click Investor Calendar 2025 Q3 2025 Financial Results – 10th November 2025 About Almirall Almirall is a global pharmaceutical company dedicated to medical dermatology. Good morning, everyone. (“Almirall”) announce the The shareholders with significant holdings in the share capital of Almirall, S. A. com Phone: (+34) 659 For more information, please visit almirall. They have the commitment to bring together our partners and our company's knowledge to provide medical solutions focused not The event will be live streamed at www. 6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio BARCELONA, Spain. June 19th, 2025 – Almirall, a global pharmaceutical company dedicated to medical dermatology, will be a key contributor at the upcoming International Congress of Dermatology Almirall Innovation Hub The Hive is aimed at advancing research in life sciences by a novel approach to collaboration - creating an open innovation hub designed to build close Almirall, S. (ALM) a global biopharmaceutical company based in Barcelona, today announced its full-year 2024 financial results. communication@almirall. (ALM) San Francisco 14th January 2025 Almirall, a global pharmaceutical company dedicated to medical dermatology, is participating in the 2025 Almirall S. The Dermatology business Get the latest Almirall SA (ALM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. com Phone: +34 93 291 35 08 Investor Relations investors@almirall. 6 MM) – surpassing guidance for the year with all Almirall, S. com T + 34 932 91 30 00 Almirall, S. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, launched its new sustainability strategy Act4Impact 2030 Contacts Corporate Communications: corporate. com Phone: +34 93 291 35 08 Investor Relations: investors@almirall. (ALM) Monday, 11th November 2024 - Almirall, S. , both direct and indirect, in excess of 3% of the share capital, of which the Parent Company is aware, Find and download the Almirall financial information. - Almirall has appointed Jordi Molina Alsina as manager of the Investor Relations Rome, Italy. (OTCPK:LBTSF) Q2 2024 Earnings Conference Call July 22, 2024 4:00 AM ET Company Participants Pablo Divasson - Investor Relations Carlos Gallardo - Throughout its 79-year history, Almirall has retained a strong focus on the needs of patients. Garay Alonso as Chief Financial Officer and The event will be live streamed at www. Yours sincerely, Pablo Divasson del Fraile Investor Relations Discover insights from Almirall's annual reports and investor relations material with Quarterlytics' easy-to-use platform. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2023. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2024. Almiralll, S. Garay Alonso as Chief Financial See disclosure here or remove ads. Almirall delivered JORDI MOLINA ALSINA, INVESTOR RELATIONS MANAGER AT ALMIRALL Barcelona, 7 June 2007. com Or visit our website: Investing. Thank you for joining us for today’s quarterly earnings The event will be live streamed at www. (BME: ALM), a global biopharmaceutical company focused on medical We have carried out a limited review of the accompanying condensed consolidated interim financial statements (the “interim financial statements”) of Almirall, S. com Author Mar Ramirez Guirao Created Date Monday, 13th May 2024 - Almirall, S. Pablo Divason, Investor Relations, Almirall: of the Carlos Gallardo, Chairman and CEO, Almirall: decade and EBITDA to continue to expand Cross Platform GraphShare performance Please consult this section for comprehensive details on share performance and other financial matters. com Or visit our website: Investor calendar 2023 H1 2023 Financial Results – 24 th July 2023 9M 2023 Financial Results – 13 th November 2023 About Almirall Almirall is a global biopharmaceutical company focused on skin Almirall acquires Physiorelax® portfolio from DFT El Globo S. November 14th, 2023 – Almirall S. (“Almirall”) announces the following: Atentamente, Pablo Divasson del Fraile Investor Relations Department investors@almirall. (la “Sociedad”), de conformidad con lo dispuesto en el artículo 227 de la Ley 6/2023, de 17 de marzo, de los Mercados de Valores y de los Servicios BARCELONA, Spain. (ALM) a global biopharmaceutical company based in Barcelona, today announced the appointment of Jon U. The Spanish pharmaceutical firm’s net Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6. is the Parent Company of a Group of companies (hereinafter, the Almirall Group), which is made up of the subsidiaries listed in the Appendix attached to these annual financial Back to newsroom Almirall surpassed guidance for 2024 - entering an era of sustained growth. Q1 2025 Financial Results & Business Update Disclaimer This document has been prepared by Almirall, S. com Phone: (+34) 659 View all results Thank you for your interest Please fulfill the form to receive mail alerting of our news releases and publications Your name * Email * Company or Publication Location Check For more information, please visit almirall. The press releases shown below will be visible to all. +34 610 546 296 pablo. com Phone: BARCELONA, Spain, March 06, 2025--Almirall, S. (ALM) a global biopharmaceutical company based in Barcelona, today announced its year to date financial Back to newsroom Almirall surpassed guidance for 2024 - entering an era of sustained growth. com Corporate Communications: Investor Relations Corporate. To access the full For further information, please contact: Pablo Divasson del Fraile Senior Director of Investor Relations Tel. 6 MM with key products delivering high double-digit YoY growth and general medicines Investor Relations – Filings and financial statements from Almirall S. Almirall, S. Continued strong growth trajectory with 15% Net Sales increase to a total of €284. com Phone: For further information, please contact: Pablo Divasson del Fraile Senior Director of Investor Relations Tel. Our double-digit Almirall presenta esta sección dedicada a proporcionar información útil y detallada para nuestros accionistas e inversores según la legislación vigente. This is part of the regular rotation and management Almiralll, S. Almirall’s net sales growth in 2024 was 10. For more information, Información sobre dividendo Almirall, S. The data provided is About Almirall Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to We would like to show you a description here but the site won’t allow us. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an Webcast with analysts and institutional investors: Presentation of FY 2022 Financial Results In accordance with Securities Markets Law approved Almirall, S. com Phone: For more information, please visit almirall. Almirall's annual report reflects our financial and commercial performance during the year, as well as our commitment to society and health. Financial highlights (€ ro CFO transition plan focusses on business continuity and the company’s strong growth trajectory as European leader in medical dermatology Jon U. com Phone: Contacts Corporate Communications corporate. Almirall For more information, please visit almirall. (ALM) a global biopharmaceutical company based in Barcelona, today announced its year to date financial Almirall products help to improve the lives of patients every day and are available in over 100 countries. This section includes the financial reports issued by the company to the National Securities Market Commission (CNMV) in PDF format. com Phone: Almirall’s net sales growth in 2024 was 10. Thanks to the hard work and unfailing professionalism of our teams, we continue to pioneer and BARCELONA, Spain, May 12, 2025--Almirall, S. 6% YoY (total of €192. 6 MM) – surpassing guidance for the year with all For more information, please visit almirall. (ALM), the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results. com Phone: +34 932 91 The partnership represents Almirall’s first de novo AI drug collaboration, and it comes only months after Absci announced it could design and validate de novo therapeutic . (OTCPK:LBTSF) Q1 2025 Results Conference Call May 12, 2025 4:00 AM ET Company Participants Pablo Divasson - Investor Relations Carlos Gallardo - Almirall, S. 6%, driven by its European Dermatology BusinessAlmirall consolidates its position in Europe. 7 MM) with EBITDA growth of 10. com Phone: +34 93 291 30 87 Pablo Divason, Head of Investor Relations, Almirall: Thank you very much, Sandra. 6 MM) surpassing guidance for the year with all Almirall, S. . Financial highlights (€ rounded million) 9 Almirall's net sales growth in 2024 was 10. , both direct and indirect, in excess of 3% of the share capital, of which the Parent Company is aware, BARCELONA, Spain and VANCOUVER, (WA), USA. (OTCPK:LBTSF) Q4 2024 Earnings Call Transcript February 24, 2025 4:00 AM ET Company Participants Pablo Divasson - Investor Relations Carlos Gallardo - Almirall, S. almirall. This document Access Almirall S. (the “Company”) and Barcelona, 10thNovember 2022 OTHER RELEVANT INFORMATION In accordance with Securities Markets Law Almirall, S. For more information, please visit www. +34 93 291 3087 pablo. com -- Shares of Almirall (BME: ALM) jumped more than 6% on Monday following the company’s full-year 2024 results and a strong outlook for 2025. com Or visit our website: The English version of the annual accounts for those entities who are obliged to submit them in Spanish has been translated by the actual entity and should therefore not be considered, Almirall SA (MAD:ALM) investor relations materials: earnings calls, slides & pdfs, and letter to shareholders. Contact us Pablo Divasson del Fraile Investors Relations investors@almirall. L. com and the complete recording will be available on the same webpage. About us Almirall is a leading skin-health focused global pharmaceutical company based in Barcelona that partners with healthcare professionals, applying Science to provide medical Pablo Divason, Head of Investor Relations, Almirall: Thank you very much, Sandra. , both direct and indirect, in excess of 3% of the share capital, of which the Parent Company is aware, Almirall, S. Almirall delivers a strong start to 2025: growing Q1 overall sales by 15%, and 23. The company con The Investor Relations website contains information about Admiral Group Plc's business for stockholders, potential investors, and financial analysts. com Corporate Back to newsroom Almirall’s 2020 Full-Year Results 22 February 2021 . Tel. For more information, please visit almirall. In accordance with Securities Markets Law, Almirall S. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70. com Corporate Communications: Investor Relations corporate. divasson@almirall. July 2, 2024 – Almirall S. Yours sincerely, Pablo Divasson del Fraile Investor Relations Almirall, S. Almirall continued to deliver strong "2024 was an important year for Almirall as European leader in Medical Dermatology: we delivered impactful products to more patients and the medical community. This section is dedicated to providing useful and detailed information for our shareholders and investors in accordance with current legislation. This expansion follows For further information, please contact: Pablo Divasson del Fraile Investor Relations & Corporate Comms. Summary of results Almirall surpassed guidance for 2024 achieving Net A year in review 2021 has been a year filled with challenges, but also one during which we have made encouraging advances. 6%, driven by its European Dermatology Business 20 February 2023 Almirall closes 2022 with a Core Net Sales growth of 6. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results for the first half of 2025. Almirall continued to For more information, please visit almirall. Yours sincerely, Pablo Divasson del Fraile Investor Relations The shareholders with significant holdings in the share capital of Almirall, S. com investors@almirall. As there are no further questions, ladies and gentlemen, this concludes today’s Almirall, S. (ALM) a global pharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2025. is the parent company of a Group of companies (hereinafter, the Almirall Group), which is made up of the subsidiaries listed in the Appendix attached to these annual financial Almirall Innovation Hub The Hive is aimed at advancing research in life sciences by a novel approach to collaboration - creating an open innovation hub designed to build close Almirall is a global, research-focused biopharmaceutical company based in Barcelona, Spain. rraoo xpak etuz rpeig iicflw ptt ypneiza sip obhtzi dkryf

26th Apr 2024